Public health officials now have a powerful new tool to track vaccination coverage during Ebola outbreaks, addressing a critical gap in surveillance capabilities. The ability to definitively confirm who has received the ERVEBO vaccine versus who survived natural infection has profound implications for outbreak response strategies and population immunity assessments.
Researchers developed a sophisticated multiplex blood test that identifies three distinct protein signatures: the standard Ebola glycoprotein, secreted glycoprotein, and a modified vesicular stomatitis virus nucleoprotein unique to the ERVEBO vaccine. Testing samples from US vaccinees and controls, plus comparison groups from the Democratic Republic of Congo, the assay achieved 100% sensitivity and over 97.6% specificity for vaccine detection. Field validation during Guinea's ring vaccination campaign confirmed vaccination status in 94.8% of individuals with written records and 90.8% with verbal confirmation.
This breakthrough addresses a fundamental limitation in Ebola preparedness. Previous serologic tests could detect antibodies but couldn't distinguish their source, creating blind spots in understanding true population immunity. The new assay's precision becomes crucial as ERVEBO deployment expands across at-risk regions in Africa. For global health security, accurate vaccination tracking enables more targeted outbreak responses and better resource allocation. The technology also establishes a methodological template for developing similar confirmatory tests for other emergency-use vaccines, potentially transforming how we monitor vaccination coverage during health crises when traditional record-keeping systems may be compromised.